These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7083242)

  • 21. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
    Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
    Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazofurin enhancement of 5-azacytidine antitumor activity in L5178Y and human leukemia cells.
    Cadman E; Eiferman F; Heimer R; Davis L
    Cancer Res; 1978 Dec; 38(12):4610-7. PubMed ID: 82479
    [No Abstract]   [Full Text] [Related]  

  • 26. [Neutropenic typhlitis: a frequently missed complication of aplasia-inducing tumor therapy with a possible association to the combination of etoposide with high-dose cytosine-arabinoside].
    Benz G; Gmür J; Gubler J
    Schweiz Med Wochenschr; 1994 Feb; 124(5):186-92. PubMed ID: 8128200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):907-14. PubMed ID: 8489297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential vincristine, arabinosylcytosine and adriamycin in acute leukemia: cytologic and cytokinetic studies.
    Riccardi A; Mazzini G; Montecucco C; Cresci R; Traversi E; Berzuini C; Ascari E
    Cytometry; 1982 Sep; 3(2):104-9. PubMed ID: 7140479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs.
    Park CH; Wiernik PH; Morrison FS; Amare M; Van Sloten KV; Maloney TR
    Cancer Res; 1983 May; 43(5):2346-9. PubMed ID: 6572563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
    J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission-induction regimens in acute nonlymphocytic leukemia.
    Brennan DC; Lewis JP
    West J Med; 1980 Oct; 133(4):279-88. PubMed ID: 7347042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.